Disease · MONDO_0004648

vascular dementia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. vascular dementia. Diseases, record MONDO_0004648. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004648

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: vascular dementia; Open Targets
Open Targets ID: MONDO_0004648; Open Targets
Other names: Arteriosclerotic Dementias, Dementias, Vascular, Vascular Dementias; Open Targets
Disease Ontology: DOID:8725; Disease Ontology
MeSH: D015140; MeSH
NCI Thesaurus: C34525; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 4 of its 17 drugs, from ClinicalTrials.gov; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DONEPEZIL	CHEMBL502	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
RIVASTIGMINE	CHEMBL636	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GALANTAMINE	CHEMBL659	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
GALANTAMINE HYDROBROMIDE	CHEMBL1555	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ERGOLOID MESYLATES	CHEMBL2311030		Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FERULATE	CHEMBL32749	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MARAVIROC	CHEMBL256907	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TADALAFIL	CHEMBL779	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets76

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ACHE	Acetylcholinesterase	4	Acetylcholinesterase inhibitor; Cholinesterases; ACHE & BCHE inhibitor	Phase 3	https://conductscience.org/library/genes/43	Drugs and targets
ADRA1A	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Phase 2	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Phase 2	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Phase 2	https://conductscience.org/library/genes/146	Drugs and targets
ADRA2A	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Phase 2	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Phase 2	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha	1	Adrenergic receptor alpha antagonist	Phase 2	https://conductscience.org/library/genes/152	Drugs and targets
BCHE	Cholinesterases; ACHE & BCHE	1	Cholinesterases; ACHE & BCHE inhibitor	Phase 3	https://conductscience.org/library/genes/590	Drugs and targets
CCR5	C-C chemokine receptor type 5	1	C-C chemokine receptor type 5 antagonist	Phase 2	https://conductscience.org/library/genes/1234	Drugs and targets
COXFA4	Mitochondrial complex I (NADH dehydrogenase)	1	Mitochondrial complex I (NADH dehydrogenase) inhibitor	Early phase 1	https://conductscience.org/library/genes/4697	Drugs and targets

1 to 10 of 76

See all 76 targets

Trials17

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00889603	Non-Interventional Study With Aricept® Evess		370	2011-03-31	Alzheimer's Disease, Vascular Dementia	DONEPEZIL	Its record names the disease	ClinicalTrials.gov
NCT00174382	Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia	Phase 3	149	2009-06-12	Dementia, Vascular, Dementia, Mixed	DONEPEZIL	Its record names the disease	ClinicalTrials.gov
NCT04219774	NeuroCognition After Carotid Recanalization	Phase 2	25	2025-05-09	Cognition Disorder, Stroke, Occlusion Carotid	ASPIRIN, CLOPIDOGREL	Its record names the disease	ClinicalTrials.gov
NCT00814502	Zolpidem CR and Hospitalized Patients With Dementia	Not applicable	20	2017-05-22	Dementia, Alzheimer Disease, Dementia, Vascular, Sleep Disorders, Circadian Dysregulation	ZOLPIDEM	Its record names the disease	ClinicalTrials.gov
NCT00099216	Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia	Phase 3	708		Vascular Dementia	RIVASTIGMINE	Its record names the disease	ClinicalTrials.gov
NCT00261573	A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia	Phase 3	593		Alzheimer Disease, Vascular Dementia	GALANTAMINE HYDROBROMIDE	Its record names the disease	ClinicalTrials.gov
NCT02453932	Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia	Phase 3	543		Vascular Dementia	DONEPEZIL	Its record names the disease	ClinicalTrials.gov
NCT00130338	Rivastigmine Capsules in Patients With Probable Vascular Dementia	Phase 3	521		Vascular Dementia	RIVASTIGMINE	Its record names the disease	ClinicalTrials.gov
NCT00035191	A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia	Phase 3	254		Dementia, Vascular	GALANTAMINE	Its record names the disease	ClinicalTrials.gov
NCT01475578	Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)	Phase 2	240		Vascular Dementia	ERGOLOID MESYLATES	Its record names the disease	ClinicalTrials.gov

1 to 10 of 17

See all 17 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Zolpidem CR vs Placebo: deaths from any cause	0 of 8	0 of 9	17	NCT00814502	Trial comparisons
Zolpidem CR vs Placebo: serious adverse events	0 of 8	0 of 9	17	NCT00814502	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
11965273	RESULT	1	PubMed
41332889	DERIVED	1	PubMed
40718899	DERIVED	1	PubMed
39498781	DERIVED	1	PubMed
39210472	DERIVED	1	PubMed
33189083	DERIVED	1	PubMed
32054507	DERIVED	1	PubMed
18674411	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004648

GET https://conductscience.org/api/diseases/v1/MONDO_0004648/targets?page=2

API reference For AI assistants